AbbVie(ABBV) surged out of the gate following its January 2013 spinoff from Abbott Laboratories(ABT). By December 2014, the stock price had doubled. Since then, however, the stock languished, continuing to trade below its December 2014 highs. Despite efforts to diversify, Humira, which is now off patent, accounts for 60% of revenue. Barron’s reports that Raymond James now thinks… Read More »
It’s a few weeks old now, but with AbbVie’s(ABBV) spin from Abbott Laboratories(ABT) complete, we thought it worthwhile to mention this piece from Morningstar on AbbVie’s prospects. No doubt, the new company has many things going for it. A strong balance sheet is one: Following the split from Abbott, AbbVie will carry approximately $16 billion in debt and… Read More »
Abbott Laboratories(ABT) is joining the parade and splitting itself into two. Like many other recent spinners, Abbott is a spinoff veteran, having spun off Hospira(HSP) in 2004. Though at times, even recently, Hospira has traded much higher, on the whole, returns for the two pieces 7 years later have been unimpressive. Hospira is now barely up 10%, and… Read More »